Guardant Health
331 hedge funds and large institutions have $3.7B invested in Guardant Health in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 116 increasing their positions, 108 reducing their positions, and 72 closing their positions.
206% more call options, than puts
Call options by funds: $115M | Put options by funds: $37.5M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
7% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 108
0.08% more ownership
Funds ownership: 90.82% → 90.9% (+0.08%)
7% less funds holding
Funds holding: 355 → 331 (-24)
28% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 72
40% less capital invested
Capital invested by funds: $6.11B → $3.7B (-$2.42B)
Top Buyers
Top Sellers
GH Hedge Fund Activity: Q2 2022 in Review
331 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Guardant Health (GH) for Q2 2022, worth a combined $3.7B — down 40% from $6.11B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of GH and 52 opened new positions — a net loss of 20 holders — while 108 trimmed existing stakes and 116 added.
The largest buyer was Fidelity Investments, adding an estimated $260M. The largest seller was Capital Research Global Investors, cutting an estimated $92.2M.
- 331 institutional investors held Guardant Health (GH) as of Q2 2022, down from 355 in Q1 2022.
- Funds reported $3.7B of Guardant Health stock for Q2 2022, down 40% quarter-over-quarter.
- 52 funds opened new Guardant Health positions in Q2 2022 and 72 closed out, a net change of -20 holders.
- The largest Guardant Health buyer in Q2 2022 was Fidelity Investments, an estimated $260M added.
- The largest Guardant Health seller in Q2 2022 was Capital Research Global Investors, an estimated $92.2M sold.
Based on aggregated 13F filings for Q2 2022.